Trump Stumped IT and Pharma

Days after Donald Trump took over the Oval office in White House, Indian IT honchos and pharmaceutical industry leaders started feeling the heat of summer even in the spring. Are they prepared enough to tackle the odds posed by the Trump administration and protect interest of their shareholders -- Lohit Bharambe and Abhishek Kumar explore:

- Lohit Bharambe And Abhishek Kumar

Newly elected protectionist US President Donald J Trump has evoked fear across the world on his forthcoming economic policies. Especially, the IT industry is feeling severe tremors on account of financial instability and uncertainty pertaining to the sector. IT companies that are having majority of their exposure in the US will be facing very difficult times ahead if the proposed policy changes go through in the upcoming quarters.

The actions taken by Trump such as banning visas for several countries and introducing H-1B visa reform in the US Congress. The US and China trade war will also lead to major consequences for the emerging economies.

Here is an exclusive report on Trump’s impact on the most crucial sectors, IT and pharmaceuticals.

H-1B VISA BILL IN USA

What is a H-1B visa?

The H-1B visa is a non-immigrant visa given by the United States to employ skilled workers from other countries for various specialised fields of occupation for a certain period of time.

What is the H-1B Visa Programme Bill?

The Bill prohibits companies from hiring H-1B employees if they employ more than 50 people and more than 50 per cent of their employees are H-1B and L-1 visa holders. The Bill encourages companies to recruit American workers. This provision would crack down on outsourcing companies that import large numbers of H-1B and L-1 workers for short training periods and then send these workers back to their home country to do the work of Americans, according to the Senators who introduced the Bill.

H-1B Visa Top Sponsors